Description,Variable,SummaryType,Target,Ref,TargetValue,AbsoluteTol,CrabbitTarget
,,,,,,,
Medical history,,,,,,,
ASCVD(%),isASCVD,Proportion,100,,100,0,
Polyvascular ASCVD(%),isPolyVD,Proportion,,,,,
Coronary revasc(%),isPriorRevasc,Proportion,0,,0,0,
Myocardial infarction(%),isPriorChd,Proportion,100,,100,5,
Ischemic stroke(%),isPriorCbvd,Proportion,3.8,https://jinko.ai/as-1sWB-INf5,3.8,1.5,OK
Symptomatic PAD(%),isPriorPad,Proportion,5.55,https://jinko.ai/as-cHYs-1BPK,5.55,1.5,OK
Patient characteristics,,,,,,,
Age - yr (mean (SD)),ageInit,MeanSD,63.6(9.75),https://jinko.ai/as-cHYs-1BPK,63.6,3,OK
Male sex(%),isMaleSex,Proportion,75.7,https://jinko.ai/as-cHYs-1BPK,75.7,5,OK
Body mass index - kg/m2 (mean (SD) or median (Q1-Q3)),BMI,MeanSD,28.3(5.2),https://jinko.ai/as-cHYs-1BPK,28.3,1,OK
BMI 25-30 - %,isBMIBetween25And30,Proportion,,,,,
BMI > 30 kg/m2 - %,isBMIAbove30,Proportion,,,,,
Mean sitting SBP,systolicBloodPressure,MeanSD,,,,2,
Mean sitting DBP,diastolicBloodPressure,MeanSD,,,,2,
Atrial fibrillation,isAtrialFibrillation,Proportion,,,,1,
Heart failure,isHeartFailure,Proportion,4.35,https://jinko.ai/as-cHYs-1BPK,4.35,1,OK
CV risk factors(%),,,,,,,
Current smoker,isSmoking,Proportion,33,https://jinko.ai/as-cHYs-1BPK,33,2,OK
Diabetes,isDiabetes,Proportion,27.2,https://jinko.ai/as-cHYs-1BPK,27.2,2,OK
Estimated HeFH,isHeFH,Proportion,6,,,2,
Concomitant therapy(%),,,,,,,
Aspirin/Antiplaquettaire,isAspirin,Proportion,97,https://jinko.ai/as-cHYs-1BPK,97,5,OK
Rosuvastatin,IMPROVE-IT-placebo_isRVALLT,Proportion,,,,,
Atorvastatin,IMPROVE-IT-placebo_isAVALLT,Proportion,,,,,
Moderate-intensity statin,IMPROVE-IT-placebo_isModIntStatinMono,Proportion,,,,5,
High-intensity statin,IMPROVE-IT-placebo_isHighIntStatin,Proportion,,,,5,
Ezetimibe combination,IMPROVE-IT-placebo_isHighIntStatinEze,Proportion,,,,2.5,
Biological measures at one year - mg/dL & mmol/L,,,,,,,
LDL-C,IMPROVE-IT-placebo_valueLDLcUncorrectedMassY1,MedianIQR,67 (55-81),https://jinko.ai/as-9mT0-rQzc,67,8,OK
TC,IMPROVE-IT-placebo_valueTotalCholMassY1,MedianIQR,142 (126-160),https://jinko.ai/as-9mT0-rQzc,142,8,OK
Non-HDL-C,IMPROVE-IT-placebo_valueNonHDLCholMassY1,MedianIQR,93 (79-110),https://jinko.ai/as-9mT0-rQzc,,8,
HDL-C,IMPROVE-IT-placebo_valueHDLcMassY1,MedianIQR,46 (39-55),https://jinko.ai/as-9mT0-rQzc,,4,
Apo-B,IMPROVE-IT-placebo_valueApoBY1,MedianIQR,79 (67-93),,,8,
Triglycerides,IMPROVE-IT-placebo_valueTriglyceridesMassY1,MedianIQR,116 (84-165),https://jinko.ai/as-9mT0-rQzc,116,10,OK
Lipoprotein(a) - mg/dL,IMPROVE-IT-placebo_valueLpaSubstanceY1,MedianIQR,,,,10,
PCSK9 - Î¼g/L,IMPROVE-IT-placebo_valueFreePCSK9Y1,MeanSD,,,,20,
Biological measures - mg/dL,,,,,,,
hsCRP - mg/dL med. (range),IMPROVE-IT-placebo_valueCRPY1,MedianIQR,1.6 (0.8-3.6),https://jinko.ai/as-9mT0-rQzc,1.6,0.5,OK
eGFR - mL/min/1.73 m2,eGFR,MeanSD,,,,5,
Severe (eGFR < 30),isEgfrBelow30,Proportion,,,,,
Moderate (eGFR 30-59),isEgfrBetween30And59,Proportion,,,,,
CKD > G2 (eGFR<60),isEgfrBelow60,Proportion,,,,,
Control arm outcomes (%),,,,,,,
MACE (%),IMPROVE-IT-placebo_isMACE,Proportion,22.2,https://jinko.ai/as-d14i-YhnM,22.2,1,OK
CV death (%),IMPROVE-IT-placebo_isCvDeath,Proportion,6.8,https://jinko.ai/as-d14i-YhnM,6.8,1,OK
Myocardial infarction(%),IMPROVE-IT-placebo_isMI,Proportion,14.8,https://jinko.ai/as-d14i-YhnM,14.8,1,OK
Ischemic stroke(%),IMPROVE-IT-placebo_isIscStroke,Proportion,4.1,https://jinko.ai/as-d14i-YhnM,4.1,1,OK
Symptomatic PAD(%),IMPROVE-IT-placebo_isMajorAdverseLimbEvent,Proportion,,,,1,
Fatal MI(%),IMPROVE-IT-placebo_isFatalMI,Proportion,0.7,https://jinko.ai/as-d14i-YhnM,0.7,1,OK